BMJ4d
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Objectives Metabolic changes are crucially involved in osteoclast development and may contribute to bone degradation in rheumatoid arthritis (RA). The enzyme aconitate decarboxylase 1 (Acod1) is known ...
BMJ2d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
BMJ7d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ7d
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
1 Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China 2 Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, ...
BMJ3d
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to ...
BMJ7d
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
2 Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria Objective The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of ...
BMJ4mon
Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis
Objectives This project aimed to determine whether cranial ischaemic complications at the presentation of giant cell arteritis (GCA) were associated with pre-existing cardiovascular (CV) risk factors, ...
BMJ7d
Stage-specific and location-specific cartilage calcification in osteoarthritis development
Correspondence to Professor Hongwei Ouyang, 1. Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, and Department of Orthopedic Surgery of the Second Affiliated Hospital, ...
BMJ7d
TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis
Objective We investigated genome-wide changes in gene expression and chromatin remodelling induced by tumour necrosis factor (TNF) in fibroblast-like synoviocytes (FLS) and macrophages to better ...
BMJ7d
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised ...
BMJ8d
Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade
Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...
BMJ7d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...